Assessment of new formulations of inactive Transialidase to achieve immunoprotection against Trypanosoma cruzi infection

IVAN A BONTEMPI; MIGUEL H VICCO; ALEJANDRO MONTANER; NICO CALLEWAERT; IVAN S MARCIPAR

Cordoba

Congreso; LXI REUNIÓN ANUAL Sociedad Argentina de Inmunología (SAI); 2013

Sociedad Argentina de inmunología

In a previous work, high levels of immunoprotection had been achieved in Balb/c mice infected with T.cruzi, when inactivated transialidase (iTS) formulated with Freund´s adjuvant (FA) was immunized. However FA is a non-authorized adjuvant for vaccine design. Herein we have compared FA formulation of iTS with new formulations using humans potentially applicable adjuvants: the immunostimulatory ISCOMATRIX (IMX) and the Oligonucleotide IMT504 (ODN). We inoculated groups of BALB/c with: iTS-IMX (10 ug iTS and 5 ug IMX); iTS-FA (10ug iTS in 50 ul with 50 ul FA); iTS-ODN (10 ug iTS and 500 ug ODN); iTS (10 ug of iTS, without adjuvant) or PBS (control group). High levels of specific anti-iTS antibodies had been developed after the third inoculation in all iTS-immunized groups (P